**Core Concept**
The emergence of drug-resistant HIV strains, such as those with the Y181C mutation, poses a significant challenge in the management of HIV infection. This mutation affects the CCR5 receptor antagonist class of antiretroviral drugs, which are critical in the treatment of HIV.

**Why the Correct Answer is Right**
The Y181C mutation is associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of antiretroviral drugs. However, **doravirine** is an NNRTI that retains its efficacy against HIV strains with the Y181C mutation. This is because doravirine has a unique binding profile and resistance profile compared to other NNRTIs, making it effective against this specific mutation.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because the drug is not effective against the Y181C mutation.
**Option B:** This option is incorrect because the drug is not a suitable choice for patients with this specific mutation.
**Option C:** This option is incorrect because the drug is not effective against the Y181C mutation.

**Clinical Pearl / High-Yield Fact**
Doravirine is a valuable option for patients with HIV who have developed resistance to other NNRTIs, including those with the Y181C mutation. It is essential to consider the specific resistance profile of the patient when selecting an antiretroviral regimen.

**Correct Answer:** C. Doravirine